USA EQUITIES CORP. (OTCMKTS:USAQ) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On December 30, 2020, USA Equities Corp. (the “Company”) issued a press release entitled “USA Equities Corp (USAQ), Announces Revenues of $120,000 for the 4th Quarter of 2020 and Projects Revenues in excess of $300,000 for the 1st Quarter of 2021”.
A copy of the above-mentioned press release is attached herewith as Exhibit 99.1.
By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD. The Company uses, and will continue to use, its website, press releases, and various social media channels, including its Twitter account (https://twitter.com/mpi_usaq), its LinkedIn account (https://www.linkedin.com/company/medicalpracticeincome/) its Facebook account (https://www.facebook.com/medicalpracticeincome), as additional means of disclosing public information to investors, the media and others interested in the Company. It is possible that certain information that the Company posts on its website, disseminated in press releases and on social media could be deemed to be material information, and the Company encourages investors, the media and others interested in the Company to review the business and financial information that the Company posts on its website, disseminates in press releases and on the social media channels identified above, as such information could be deemed to be material information.
ITEM 9.01 Financial Statements and Exhibits
|99.1||Press release entitled “USA Equities Corp (USAQ), Announces Revenues of $120,000 for the 4th Quarter of 2020 and Projects Revenues in excess of $300,000 for the 1st Quarter of 2021” dated December 30, 2020|
USA EQUITIES CORP. Exhibit
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 “USA Equities Corp (USAQ),…
To view the full exhibit click
About USA EQUITIES CORP. (OTCMKTS:USAQ)
USA Equities Corp., formerly American Biogenetic Sciences, Inc., is a shell company. The Company focuses to seek new business opportunities, including seeking an acquisition or merger with an operating company. The Company’s subsidiary, USA Equities Trust, Inc., is engaged in acquiring real estate. The Company was engaged in the research, development and marketing of cardiovascular and neurobiology products for the purpose of commercial development and vaccines distribution. The Company’s products were designed for in vitro and in vivo diagnostic procedures and therapeutic drugs, and its products had been identified for use in the treatment of epilepsy, migraine and mania, neurodegenerative diseases, coronary artery diseases and cancer. The Company has no operations.